SCOTUS declines to take up 'skinny' label generic drug case, raising questions about future carve outs
The Supreme Court decided on Monday to not take up a controversial court decision that may have ripple effects across the generic drug industry. The …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
